In a report published Monday, Bank of America Merrill Lynch resumed coverage on MannKind Corporation MNKD with a Buy rating and $3.00 price objective.
BofA Merrill Lynch noted, “We are resuming coverage of MNKD and upgrading to Buy. While the stock is not inexpensive (current enterprise value is $800mn), we see relatively modest risk in coming quarters, and believe the next meaningful catalyst (phase 3 read-out in mid-2013) has a high probability of being favorable. The type 2 study uses Afrezza as add-on therapy in patients on oral drugs and with A1c levels above 7.5%. With 90% power to show at least a 0.3% A1c reduction (our estimate), we believe these results will be statistically significant. The second trial in type 1 patients is a basal/bolus insulin non-inferiority study that utilizes an independent monitoring committee to review patient e-diaries to assure proper titration, which could leverage Afrezza's PK profile in our view. Our DCF-derived PO is $3/sh, based on 2% peak share of prandial insulin and 3% peak in oral combo patients.”
MannKind Corporation closed on Friday at $1.98.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in